文献速递免疫规划

12月龄以下婴儿接种含麻疹疫苗后不良事件的系统综述与Meta分析

A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age.
PubMed 文献 · Vaccine · 2025-01-11

该系统综述与Meta分析检索EMBASE和PubMed(2021年2月,2024年2月更新),纳入24项研究(18项随机对照试验、3项干预性研究、3项观察性研究),仅1项随机对照试验为安慰剂对照,评估12月龄以下婴儿接种MCV1后56天内不良事件频率。任何不良事件频率通常<10%,安慰剂对照试验显示MCV1与安慰剂注射婴儿间无差异;Edmonston B株和MMRV与>39°C高热率较高相关。

要点

  • 12月龄以下婴儿接种MCV1后任何不良事件频率通常<10%。
  • 唯一安慰剂对照试验显示MCV1与安慰剂注射婴儿间无差异。
  • Edmonston B株和MMRV与>39°C高热率较高相关。

核心结论

  • 大多数不良事件发生在<12月龄接种MCV1婴儿中的<10%。
  • 安慰剂对照试验提示早期MCV接种后无超额反应原性。
  • 麻疹毒株和疫苗效价可能影响不良事件风险,但社会经济状况、种族和研究环境等其他因素也可能解释该发现,因这些因素在研究间分布不均。
  • 解读无安慰剂组的研究结果时需谨慎。

研究设计与样本

  • 系统综述与Meta分析,检索EMBASE和PubMed(2021年2月,2024年2月更新)。
  • 纳入除外病例报告的1985年后发表的英文原创研究,需包含<12月龄婴儿接种MCV1后56天内不良事件频率指标。
  • 共纳入24项研究:18项随机对照试验、3项干预性研究、3项观察性研究;仅1项随机对照试验为安慰剂对照。

主要发现

  • 常见报告的不良事件为注射部位反应、发热、皮疹、胃肠道症状、呼吸道症状、结膜炎及与婴儿一般状况相关的症状。
  • 任何不良事件的频率通常<10%。
  • 安慰剂对照试验显示MCV1与安慰剂注射婴儿间无差异。
  • Edmonston B株和麻疹-腮腺炎-风疹-水痘疫苗(MMRV)与>39°C高热率较高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仅1项随机对照试验为安慰剂对照。
  • 麻疹毒株和疫苗效价可能影响不良事件风险,但社会经济状况、种族和研究环境等其他因素也可能解释该发现,因这些因素在研究间分布不均。
  • 解读无安慰剂组的研究结果时需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lowering the age for receiving the first dose of a measles-containing vaccine (MCV1) has been suggested to close the emerging immunity gap in infants. However, tolerability remains one of the main concerns for vaccine-hesitant parents. We conducted a systematic review and meta-analysis of reactogenicity following MCV1 in infants under 12 months of age. METHODS: We searched EMBASE and PubMed in February 2021. The search was updated in February 2024. With exception of case reports, we included all English-written original studies published >1985 that contained frequency measures on adverse events (AEs) within 56 days following MCV1 in infants <12 months of age. We identified all common AEs and their frequencies and combined these across studies in a meta-analysis. The effect of measles strain and vaccine valency was also evaluated. FINDINGS: We included 24 studies for analysis: 18 randomized controlled trials (RCTs), three interventional studies, and three observational studies. Only one RCT was placebo-controlled. Commonly reported AEs were injection site reactions, fever, rash, gastrointestinal symptoms, respiratory tract symptoms, conjunctivitis, and symptoms related to the general condition of the infant. The frequency of any AE was generally <10 %; however, the placebo-controlled trial showed no difference between MCV1 and placebo-injected infants. Edmonston B strains and measles-mumps-rubella-varicella vaccine (MMRV) were associated with a higher rate of high fever >39 °C. INTERPRETATION: Most AEs occurred in <10 % of infants receiving MCV1 at < 12 months of age. The placebo-controlled trial suggested no excess reactogenicity following early MCV. Measles strain and vaccine valency may affect AE risks, but other factors such as socioeconomic status, race, and setting could also explain this finding, as these were not equally distributed between studies. Caution is advised when interpreting findings from studies without a placebo group.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vittrup DM, Charabi S, Jensen A, et al. A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age. Vaccine. 2025. PMID: 39799850. doi:10.1016/j.vaccine.2024.126687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。